OBJECTIVES: Ipilumumab is a clinically proven treatment option for pre-treated metastatic melanoma (MM).  Ipilumumab has clearly demonstrated survival benefit, that is prolonged in a proportion of the responding patients. Karweit J and colleagues (2012) demonstrated that mean overall survival (OS) can be particularly useful for agents with a right-skewed survival curve where a subset of patients respond to treatment with long term survival. The research has demonstrated that several agents, including ipilimumab for MM, bevacizumab for non-small cell lung cancer, sorafenib for hepatocellular carcinoma, lenalidomide for multiple myeloma and trastuzumab for metastatic breast cancer (among others) have shown greater mean OS improvement than median OS improvement, reflecting the long term survival benefit for some patients. In this analysis we select oncologic agents that have demonstrated mean OS benefit in the above mentioned study and have received license in Mexico.  We compare the relative economic value delivered by each asset, which broadly represent the therapeutic oncologic class. METHODS: The economic value of the analogues is estimated for the Mexican private perspective in terms of cost per month of mean OS versus comparators.  The analysis relies on the cost to treat to mean progression by the months of mean OS improvement. RESULTS: Cost per month of OS for ipilimumab ($15,993 USD)when compared to bevacizumab, sorafenib, trastuzumab, sunitinib, lenalidomide and vemurafenib is below the average relative cost of the assets(range from $35,871 to $9,845 USD). CONCLUSIONS: This study demonstrates that ipilimumab is a competitive asset in terms of value for money. The analysis allows to evaluate within a clear and robust analytical framework, the reimbursement decisions across the oncologic therapeutic class in Mexico.